Researcher profile
Richard A. Miller, MD, PhD
The ITP is the only program that tests candidate longevity drugs in genetically heterogeneous mice at three independent sites simultaneously. It is the reason we know rapamycin works late in life and that fisetin does not extend lifespan.
- Role
- Principal investigator, NIA Interventions Testing Program
- Affiliation
- Professor of Pathology, University of Michigan
- Topics
- Rapamycin · Senolytics · Research methods
- Their work
- Search PubMed nia.nih.gov
Why we quote Miller
The ITP is the only program that tests candidate longevity drugs in genetically heterogeneous mice at three independent sites simultaneously. It is the reason we know rapamycin works late in life and that fisetin does not extend lifespan.
Richard A. Miller, MD, PhD is one of the researchers quoted here; the others quoted alongside Richard are listed with the same disclosures.
Where they stand, and who pays
Publicly funded, sells nothing, and has published null results on compounds the supplement market was already selling.
Stating this next to the quote rather than at the bottom of a disclosures page is the whole point. A concession made against a commercial interest is stronger evidence than a neutral summary; a claim made in line with one is weaker. You cannot weigh either without knowing which you are reading.
Everything we quote them saying
All 2 lines, verbatim, in the order they appear in the site's citation index. Each one links to the recording and to the page it is used on.
It was stunning that a drug could start as late as that and still have a full lifespan benefit.
We thought we were testing the notion that removing senescent cells would be good for you, and it turned out we were testing the notion that fisetin removes senescent cells.
Used on Fisetin Benefits: One Mouse Study, One Failed Retest , Natural Alternatives to Rapamycin: What the Claim Rests On
Pages this research informs
Each page below cites this researcher directly, so you can see the claim a quote supports in its full context.
The standing disclaimer
Richard A. Miller, MD, PhD has no relationship with Rapamycin.store and does not endorse anything on it.
- They have not reviewed this site or any page that quotes them.
- Quotes are used under fair dealing for criticism and review, each linked to its public recording so you can hear the full context.
- If a quote here misrepresents what was said, tell us and we will correct it. That correction goes to the front of the queue.
Researchers who want to set out a position in their own words, rather than be quoted, can submit a contributed article.
References
3 sources, all link-checked; oldest check
- Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. International Committee of Medical Journal Editors, updated 2025.The conflict-of-interest and authorship conventions this desk follows for a lay publication.Verified Sep 14, 2026
- PubMed. US National Library of Medicine, National Institutes of Health.The index every citation on this site is checked against before publication.Verified Sep 14, 2026
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH et al. BMJ 2008;336:924.The framework behind the strong / mixed / limited evidence grades used across this site.Verified Sep 14, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.